IL32 and melanoma: In line with the human data, the most salient feature of IL-32–treated B16F10 melanomas was a chemokine-rich TME, concomitant with enhanced frequencies of activated, tumor-specific CD8+ T cells, recapitulating the findings from human melanoma TCGA samples.